• Globe Newswire

Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML

Globenewswire -

• Globe Newswire

Quantexa Named as a Category Leader in Chartis Research’s 2025 AML Transaction Monitoring and KYC Solutions Reports

Globenewswire -

• Globe Newswire

Eastnets and Facephi forge strategic alliance to create comprehensive global fraud defense ecosystem

Globenewswire -

• Globe Newswire

Quantexa Recognized as Category Leader in Chartis’ 2024 AML Transaction Monitoring Solutions Report

Globenewswire -

• Globe Newswire

Quantexa Recognized as a “Luminary” in Celent’s 2024 Insurance Fraud Detection Solutions Report

• Globe Newswire

Quantexa Debuts Q Assist, New Context Aware Generative AI Technology Suite

• Globe Newswire

Quantexa Appoints Industry Luminaries to its Advisory Board to Accelerate Growth Plans